Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-S
Cushing's disease results from adrenocorticotropic hormone (ACTH) secretion by corticotroph pituitary neuroendocrine tumors (PitNETs). Magnetic resonance imaging (MRI) is the reference modality for etiological diagnosis but may to visualize small corticotroph microadenomas in up to 30% of the cases, and false positives
| Condition(s) | Cushing Disease, ACTH-producing Pituitary Tumour |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Cushing's disease results from adrenocorticotropic hormone (ACTH) secretion by corticotroph pituitary neuroendocrine tumors (PitNETs). Magnetic resonance imaging (MRI) is the reference modality for etiological diagnosis but may to visualize small corticotroph microadenomas in up to 30% of the cases, and false positives may occur. The study hypothesis is that positron emission tomography (PET) using \[18F\]fluoroethyl-L-tyrosine (\[18F\]FET) improves localization of ACTH-secreting corticotroph microadenomas compared with MRI and could inform surgical planning and reduce reliance on invasive inferior petrosal sinus sampling. This observational cohort (retrospective and prospective data) will assess the diagnostic performance of \[18F\]FET PET for tumor localization using postoperative histop |
| Who can participate | Inclusion Criteria: * Adults (≥18 years). * Biochemical diagnosis of Cushing's disease as part of initial management. * Pituitary MRI performed; if visible, microadenoma \<10 mm in diameter. * Indication for discussion in multidisciplinary tumor board for surgical management. Exclusion Criteria: * Minor (age \<18 years). * Macroadenoma of the pituitary. * ACTH-dependent hypercortisolism secondary to ectopic secretion. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Hospices Civils de Lyon |
| Locations | Bron, France |
| Start date | 2023-11-23 |
| NCT ID | NCT07463625 |
| Official listing | https://clinicaltrials.gov/study/NCT07463625 |